Literature DB >> 30412782

Carbapenem-resistant Acinetobacter baumannii: Current status of the problem in four Bulgarian university hospitals (2014-2016).

Tanya Strateva1, Ivo Sirakov2, Temenuga Stoeva3, Alexander Stratev4, Svetoslav Dimov5, Encho Savov6, Ivan Mitov2.   

Abstract

OBJECTIVES: A total of 226 carbapenem-resistant Acinetobacter baumannii (CRAB) isolates was collected during 2014-2016 from inpatients (age range 5-88 years) in four Bulgarian university hospitals (H1-H4) to assess their antimicrobial susceptibility and to explore carbapenem resistance mechanisms as well as the molecular epidemiology of the isolates.
METHODS: Antimicrobial susceptibility testing, multiplex PCR, DNA sequencing and electrotransformation experiments were performed. Epidemiological typing by random amplification of polymorphic DNA (RAPD)-PCR was also performed.
RESULTS: The resistance rates were as follows: imipenem, 90.7%; meropenem, 98.2%; doripenem, 100%; amikacin, 92.9%; gentamicin, 87.2%; tobramycin, 55.8%; levofloxacin, 98.2%; trimethoprim/sulfamethoxazole, 86.3%; tigecycline, 22.1%; colistin, 0%; and ampicillin/sulbactam, 41.6%. Intrinsic blaOXA-51-like genes were found in all of the isolates. The majority of the A. baumannii isolates harboured either blaOXA-23-like associated with the upstream-located ISAba1 (26.1%) or blaOXA-40/24-like (46.7%), 45 isolates (19.9%) harboured both genes, and 1 isolate harboured blaOXA-58-like surrounded by ISAba3C upstream and ISAba3 downstream. The blaOXA-58 gene was transferable by electroporation indicating its plasmid location. Epidemiological typing revealed the dissemination of nosocomial CRAB with high clonal relatedness (70% similarity threshold) belonging to six, four, three and two clusters in H1, H2, H3, and H4 hospitals, respectively.
CONCLUSIONS: The A. baumannii isolates studied were problematic nosocomial pathogens. Their multidrug resistance greatly limits therapeutic options. The persistence of endemic clones comprised of OXA carbapenemase-producing multidrug-resistant A. baumannii in the monitored hospitals over a period of ca. 3 years is of concern and requires continuous detailed investigations in the future.
Copyright © 2018 International Society for Chemotherapy of Infection and Cancer. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Acinetobacter baumannii; Carbapenem resistance; Molecular epidemiology; Multidrug resistance; OXA carbapenemases

Mesh:

Substances:

Year:  2018        PMID: 30412782     DOI: 10.1016/j.jgar.2018.10.027

Source DB:  PubMed          Journal:  J Glob Antimicrob Resist        ISSN: 2213-7165            Impact factor:   4.035


  10 in total

1.  A short synthetic peptide, based on LyeTx I from Lycosa erythrognatha venom, shows potential to treat pneumonia caused by carbapenem-resistant Acinetobacter baumannii without detectable resistance.

Authors:  William Gustavo Lima; Júlio César Moreira Brito; Maria Elena de Lima; Amanda Cristina Silva Tardelli Pizarro; Maria Auxiliadora Martins de Mello Vianna; Magna Cristina de Paiva; Débora Cristina Sampaio de Assis; Valbert Nascimento Cardoso; Simone Odília Antunes Fernandes
Journal:  J Antibiot (Tokyo)       Date:  2021-05-10       Impact factor: 2.649

2.  Rate of polymyxin resistance among Acinetobacter baumannii recovered from hospitalized patients: a systematic review and meta-analysis.

Authors:  William Gustavo Lima; Júlio César Moreira Brito; Bárbara Gatti Cardoso; Valbert Nascimento Cardoso; Magna Cristina de Paiva; Maria Elena de Lima; Simone Odília Antunes Fernandes
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2020-06-12       Impact factor: 3.267

3.  The first nationwide multicenter study of Acinetobacter baumannii recovered in Serbia: emergence of OXA-72, OXA-23 and NDM-1-producing isolates.

Authors:  Bojana Lukovic; Ina Gajic; Ivica Dimkic; Dusan Kekic; Sanja Zornic; Tatjana Pozder; Svetlana Radisavljevic; Nataša Opavski; Milan Kojic; Lazar Ranin
Journal:  Antimicrob Resist Infect Control       Date:  2020-07-06       Impact factor: 4.887

4.  Epidemiology and Diagnostics of Carbapenem Resistance in Gram-negative Bacteria.

Authors:  Patrice Nordmann; Laurent Poirel
Journal:  Clin Infect Dis       Date:  2019-11-13       Impact factor: 9.079

5.  Emergent Polymyxin Resistance: End of an Era?

Authors:  Zekun Li; Yuping Cao; Lingxian Yi; Jian-Hua Liu; Qiwen Yang
Journal:  Open Forum Infect Dis       Date:  2019-10-01       Impact factor: 3.835

6.  Correlative proteomics identify the key roles of stress tolerance strategies in Acinetobacter baumannii in response to polymyxin and human macrophages.

Authors:  Zhi Ying Kho; Mohammad A K Azad; Mei-Ling Han; Yan Zhu; Cheng Huang; Ralf B Schittenhelm; Thomas Naderer; Tony Velkov; Joel Selkrig; Qi Tony Zhou; Jian Li
Journal:  PLoS Pathog       Date:  2022-03-01       Impact factor: 6.823

7.  Minocycline Susceptibility and tetB Gene in Carbapenem-Resistant Acinetobacter baumannii in Taiwan.

Authors:  Jia-Ling Yang; Chia-Jui Yang; Yu-Chung Chuang; Wang-Huei Sheng; Yee-Chun Chen; Shan-Chwen Chang
Journal:  Infect Drug Resist       Date:  2022-05-02       Impact factor: 4.177

Review 8.  How Do Transposable Elements Activate Expression of Transcriptionally Silent Antibiotic Resistance Genes?

Authors:  Aleksander Lipszyc; Magdalena Szuplewska; Dariusz Bartosik
Journal:  Int J Mol Sci       Date:  2022-07-22       Impact factor: 6.208

9.  Constitutive Phenotypic Modification of Lipid A in Clinical Acinetobacter baumannii Isolates.

Authors:  Su-Hyun Kim; Sohyeon Yun; Woojun Park
Journal:  Microbiol Spectr       Date:  2022-07-21

10.  Epidemiological situation, laboratory capacity and preparedness for carbapenem-resistant Acinetobacter baumannii in Europe, 2019.

Authors:  Felix Lötsch; Barbara Albiger; Dominique L Monnet; Marc J Struelens; Harald Seifert; Anke Kohlenberg
Journal:  Euro Surveill       Date:  2020-11
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.